JS Skyler - Clinical Diabetes, 2004 - Am Diabetes Assoc Randomized, controlled clinical trials (RCTs), completed during the past several
years or currently underway, are defining the scientific basis of contemporary
diabetes care. In terms of glycemic control, landmark RCTs have ... Cited by 23 - Related articles - BL Direct - All 2 versions
F Wang, C Vergara, J Carabino, A Desilets, … - AMERICAN JOURNAL OF HEALTH SYSTEM …, 2004 - ASHP T hiazolidinediones are effective at achieving glycemic control in patients with
type 2 diabetes mellitus when used in combination therapy. However, this class
of insulin- sensitizing agents, which includes rosiglitazone maleate, ... Cited by 6 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org VR Aroda, RR Henry - Diabetes Spectrum, 2003 - Am Diabetes Assoc The thiazolidinediones are a unique class of oral antidiabetic agents that has
been shown to directly reduce insulin resistance at sites of insulin action,
specifically adipose tissue, skeletal muscle, and the liver. By reducing ... Cited by 7 - Related articles - BL Direct - All 2 versions
G Boden - Current Opinion in Endocrinology, Diabetes and …, 2004 - journals.lww.com Introduction The increase in obesity in the United States has reached epidemic
proportions [1]. As obesity is usually associated with an increase in insulin
resistance, it is not surprising that there has been an equally dramatic ... Cited by 8 - Related articles - BL Direct - All 2 versions
Y Aso, K Okumura, N Yoshida, K Tayama, Y … - Experimental and Clinical Endocrinology and Diabetes, 2004 - thieme-connect.com Impaired fibrinolysis in type 2 diabetes may be caused by an increased plasma
concentration of plasminogen activator inhibitor 1 (PAI-1), although the effects
of short-term hypoglycemic therapy on fibrinolytic activity are poorly ... Cited by 12 - Related articles - BL Direct - All 4 versions
M Sekiguchi, M Kurabayashi, H Adachi, H … - The American journal of cardiology, 2004 - Elsevier Restenosis after coronary stent placement occurs in 16% to 38% of patients with
coronary artery disease and remains a serious clinical problem.[1 and 2] Insulin
resistance is widely known to be 1 of the risk factors for ... Cited by 14 - Related articles - All 8 versions
DJ Kudzma - American Journal of Managed Care, 2002 - ajmc.com Abstract The thiazolidinediones (TZDs) are a new class of oral antidiabetic
agents used in the treatment of type 2 diabetes mellitus. TZDs are selective and
potent agonists of peroxisome proliferator-activated receptor-gamma, which ... Cited by 17 - Related articles - View as HTML - BL Direct - All 5 versions
G Davi, M Belvedere, S Vigneri, I Catalano, C … - Thrombosis and haemostasis, 1996 - cat.inist.fr We have previously shown that tight metabolic control by insulin therapy reduced
thromboxane-dependent platelet activation in non-insulin-dependent diabetes
mellitus(NIDDM) patients. The present study was undertaken to determine ... Cited by 16 - Related articles - BL Direct - All 3 versions
[CITATION] Epidemiology of Diabetes Interventions and Complications (EDIC): design and implementation …
